We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEW YORK, March 7 /PRNewswire/ -- On March 6, Geoffrey Henson, Chief Executive Officer for FermaVir Pharmaceuticals, Inc. (OTC:FMVR) (BULLETIN BOARD: FMVR) updated the investment community in...
NEW YORK, Dec. 28 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4) today announced that, effective January 1, 2007, Dr. Geoffrey Henson will become a consultant to...
NEW YORK, July 24 /PRNewswire/ -- On July 20, Geoffrey Henson, CEO of FermaVir Pharmaceuticals, Inc. (OTC:FMVR) (BULLETIN BOARD: FMVR) updated the investment community in an exclusive interview...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions